Showing papers in "Journal of Thoracic Oncology in 2019"
University of Colorado Denver1, Gdańsk Medical University2, University of Lausanne3, The Chinese University of Hong Kong4, Hoffmann-La Roche5, University of Michigan6, University of Toronto7, Royal North Shore Hospital8, European Institute of Oncology9, University of Grenoble10, Harvard University11
TL;DR: Retrospective analyses suggest that the echinoderm microtubule-associated protein-like 4 gene-ALK variant (EML4-ALK) may influence ALK-inhibitor treatment benefit, and alectinib continues to demonstrate superior investigator-assessed PFS versus crizotinib in untreated ALk-positive NSCLC, irrespective of EML4-alk variant.
296 citations
TL;DR: The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting and proposes some principles to optimize lung cancer biomarker discovery projects.
265 citations
TL;DR: Analysis of systemic immune responses revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8+ T cell and natural killer cell subsets in the periphery in response to anti-PD-1 therapy.
261 citations
Duke University1, Harvard University2, University of Milan3, Memorial Sloan Kettering Cancer Center4, Winthrop-University Hospital5, Sarah Cannon Research Institute6, National Health Service7, Johns Hopkins University8, Yale Cancer Center9, Beatson West of Scotland Cancer Centre10, Bristol-Myers Squibb11
TL;DR: Nivolumab monotherapy provided durable responses and was well tolerated as a third‐ or later‐line treatment for recurrent SCLC.
225 citations
Guangdong General Hospital1, Shanghai Jiao Tong University2, Tongji University3, Peking Union Medical College4, The Chinese University of Hong Kong5, Sun Yat-sen University6, Nanjing Medical University7, Zhejiang University8, Zhengzhou University9, Central South University10, Bristol-Myers Squibb11, Fudan University12
TL;DR: This is the first phase III study in a predominantly Chinese population reporting results with a programmed death 1 inhibitor and nivolumab improved OS versus docetaxel and results were consistent with global CheckMate 017 and 057 studies.
223 citations
Harvard University1, University of Rochester Medical Center2, East Carolina University3, University of Chicago4, Alcoa5, Princeton University6, University of Alabama at Birmingham7, University of Pennsylvania8, Inova Health System9, Cleveland Clinic10, Cancer Treatment Centers of America11, Vanderbilt University Medical Center12, University of Cincinnati13, Case Western Reserve University14, Duke University15, Gundersen Health System16
TL;DR: In this paper, a prospective, multicenter, cohort study that evaluated electromagnetic navigation bronchoscopy (ENB) using the superDimension navigation system (Medtronic, Minneapolis, Minnesota) is presented.
213 citations
TL;DR: EGFR/TP53/RB1-mutant lung cancers are at unique risk of histologic transformation, with 25% presenting with de novo SCLC or eventual small cell transformation.
198 citations
TL;DR: Extended follow-up of the NLST showed a similar NNS as the original analysis, and there was no overall increase in lung cancer incidence in the LDCT versus CXR arm.
197 citations
University of Pittsburgh1, Cornell University2, University of Melbourne3, University of Grenoble4, Mount Sinai Hospital5, VU University Medical Center6, University of Milan7, Memorial Sloan Kettering Cancer Center8, University Hospital of Basel9, Harvard University10, University of Mississippi Medical Center11, University of Tsukuba12, Brigham and Women's Hospital13, Science for Life Laboratory14, Seoul National University Bundang Hospital15, Taipei Veterans General Hospital16, Fudan University17, University of Turin18, Mayo Clinic19, Anschutz Medical Campus20, University of Aberdeen21, Princess Margaret Cancer Centre22, National Institutes of Health23, University of Texas MD Anderson Cancer Center24, New York University25
TL;DR: The questions cover topics such as the best IHC markers for distinguishing NSCLC subtypes, differences in thyroid transcription factor 1 clones, and the utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors.
195 citations
TL;DR: In multivariate analysis BMs are not associated with a poorer survival in patients with ICI-treated NSCLC, and stable patients with BM without baseline corticosteroids and a good ds-GPA classification have the best prognosis.
167 citations
Erasmus University Rotterdam1, Maastricht University2, Institut Gustave Roussy3, European Organisation for Research and Treatment of Cancer4, University of Manchester5, University of Grenoble6, University of Turin7, Aix-Marseille University8, Northern General Hospital9, The Royal Marsden NHS Foundation Trust10, Netherlands Cancer Institute11, Leiden University Medical Center12, Università Campus Bio-Medico13, Ghent University Hospital14, Ghent University15, European Respiratory Society16, Ben-Gurion University of the Negev17, University of Zurich18, Karolinska University Hospital19, University of Ljubljana20, Gdańsk Medical University21, University of Lausanne22, University of Barcelona23, Katholieke Universiteit Leuven24
TL;DR: A multidisciplinary consensus statement on the definition and staging of sOM-NSCLC has been formulated, which will help to standardise inclusion criteria in future clinical trials.
TL;DR: KRAS‐mutated NSCLC represents a genetically heterogeneous subgroup with a high frequency of co‐occurring mutations in cancer‐associated pathways, partly associated with distinct KRAS mutation subtypes.
Fox Chase Cancer Center1, University of Pennsylvania2, Wayne State University3, University of Texas MD Anderson Cancer Center4, Sanford Health5, University of Virginia6, University of Washington7, Cleveland Clinic8, Indiana University9, National Taiwan University10, University of California, San Francisco11, Harvard University12, Merck & Co.13, New York University14
TL;DR: The significant improvements in PFS and ORR observed in the primary analysis were maintained, and the HR for OS with a 24‐month median follow‐up was 0.56, favoring pembrolizumab plus PC.
TL;DR: For patients with KRAS-mutant NSCLC (all mutational subtypes), the efficacy of ICI is similar to that for patients with other types of NSCLCs, and this finding is especially true when PD-L1 expression is high (PD-L 1 expression ≥50%).
National Taiwan University1, Princess Margaret Cancer Centre2, Seoul National University Hospital3, Gyeongsang National University4, Seoul National University Bundang Hospital5, National Yang-Ming University6, Inje University7, I-Shou University8, Sungkyunkwan University9, AstraZeneca10, Vanderbilt University Medical Center11
TL;DR: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms, and the combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR‐TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.
TL;DR: Part‐solid lung adenocarcinoma showed clinicopathologic features different from those of pure solid tumor, and CTR, solid component size, and tumor size could not predict the prognosis.
TL;DR: In patients with T1 lung ADC with STAS, lobectomy was associated with better outcomes than sublobar resection was and the sensitivity and specificity for detecting STAS by use of FSs were 71% and 92%, with substantial interrater reliability.
TL;DR: In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to one‐third of them had another oncogenic driver, and patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.
TL;DR: Data from this large predominantly community-based study are consistent with registrational studies, and the median OS for patients with an ECOG PS of 2 was lower than for the overall population, but comparable with historical data.
TL;DR: Pretreatment and during-treatment biopsy specimens suggested that tumor immune phenotypes may be relevant for SCLC responses to immune checkpoint blockade combinations, and the predictive value of preexisting CD8-positive T-cell infiltrates observed in this study needs to be confirmed in larger cohorts.
Vanderbilt University Medical Center1, Vanderbilt University2, Stanford University3, City of Hope National Medical Center4, University of Wisconsin-Madison5, University of Texas MD Anderson Cancer Center6, Washington University in St. Louis7, University of California, San Diego8, University of Southern California9, Harvard University10
TL;DR: Clinical utility of ctDNA was demonstrated, both at pre-treatment by identifying a potential subgroup of ALK+ NSCLC patients that may derive more benefit from ensartinib and longitudinally by tracking resistance.
TL;DR: Atezolizumab monotherapy in relapsed SCLC failed to show significant efficacy and no unexpected safety concerns were observed.
TL;DR: Pembrolizumab plus erlotinib did not improve objective response rate compared with previous monotherapy studies; further evaluation would be necessary to evaluate potential effects on other efficacy outcomes.
TL;DR: Investigating the effects of prevalence changes in tobacco smoking and particulate matter (PM) 2.5 levels on lung cancer in Taiwan found that PM2.5 level changes can affect AdLC incidence and patient survival.
TL;DR: The presence of GGO components was a strong predictor in patients with invasive p-stage I NSCLC and risk factors were distinct in the part-solid and solid groups.
TL;DR: Clinopathologic and oncologic outcomes were disparate based on the presence of a GGO component in the eighth edition TNM classification of c‐stage IA lung adenocarcinoma.
TL;DR: Patients with stage IV ALK‐positive NSCLC can have prolonged OS, and each additional month of pemetrexed‐based therapy was associated with a 7% relative decrease in risk of death.
TL;DR: How MRD detection could help identify patients at increased risk of disease recurrence and thus guide treatment decisions for resectable lung cancer is discussed and future steps to validate such approaches and expand the utility of these rapidly progressing technologies are proposed.
TL;DR: Co‐occurring genomic alterations detected by panel sequencing are associated with the clinical outcomes of EGFR‐TKI treatment in NSCLC.
TL;DR: MET-TKIs inhibited the growth of cells with MET exon 14 mutations, and this finding should provide relevant clinical implication for treating patients with lung cancer harboring MET ex on 14 mutations.